Royalty Pharma (NASDAQ:RPRX) EVP Marshall Urist Sells 20,000 Shares

Royalty Pharma PLC (NASDAQ:RPRX) EVP Marshall Urist sold 20,000 shares of the firm’s stock in a transaction that occurred on Friday, January 16th. The stock was sold at an average price of $39.52, for a total transaction of $790,400.00. Following the sale, the executive vice president directly owned 40,000 shares of the company’s stock, valued at approximately $1,580,800. The trade was a 33.33% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Marshall Urist also recently made the following trade(s):

• On Friday, January 9th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The stock was sold at an average price of $40.78, for a total value of $815,600.00.
• On Friday, December 26th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The stock was sold at an average price of $39.32, for a total value of $786,400.00.
• On Friday, December 19th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The shares were sold at an average price of $38.38, for a total value of $767,600.00.
• On Tuesday, December 16th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The shares were sold at an average price of $38.32, for a total value of $766,400.00.
• On Friday, December 5th, Marshall Urist sold 23,334 shares of Royalty Pharma stock. The stock was sold at an average price of $39.15, for a total value of $913,526.10.
• On Friday, December 5th, Marshall Urist sold 18,242 shares of Royalty Pharma stock. The shares were sold at an average price of $39.15, for a total value of $714,174.30.
• On Monday, December 1st, Marshall Urist sold 23,333 shares of Royalty Pharma stock. The shares were sold at an average price of $39.93, for a total value of $931,686.69.
• On Monday, December 1st, Marshall Urist sold 18,242 shares of Royalty Pharma stock. The stock was sold at an average price of $39.90, for a total transaction of $727,855.80.

Royalty Pharma Stock Down 1.2%

Shares of NASDAQ:RPRX opened at $39.09 on Wednesday. The company has a quick ratio of 3.48, a current ratio of 3.48 and a debt-to-equity ratio of 0.89. The firm has a market cap of $22.56 billion, a P/E ratio of 29.61, a P/E/G ratio of 1.51 and a beta of 0.43. Royalty Pharma PLC has a 12 month low of $29.66 and a 12 month high of $41.70. The company’s 50-day moving average price is $39.31 and its two-hundred day moving average price is $37.48.

Royalty Pharma (NASDAQ:RPRX) last announced its earnings results on Wednesday, November 5th. The biopharmaceutical company reported $1.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.11 by $0.06. Royalty Pharma had a net margin of 32.51% and a return on equity of 26.36%. The company had revenue of $609.29 million for the quarter, compared to analyst estimates of $765.01 million. As a group, research analysts forecast that Royalty Pharma PLC will post 4.49 EPS for the current fiscal year.

Royalty Pharma Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 20th will be given a $0.235 dividend. This represents a $0.94 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date is Friday, February 20th. This is a positive change from Royalty Pharma’s previous quarterly dividend of $0.22. Royalty Pharma’s dividend payout ratio is 66.67%.

Institutional Trading of Royalty Pharma

Institutional investors and hedge funds have recently modified their holdings of the stock. CWM LLC raised its position in Royalty Pharma by 1.5% in the third quarter. CWM LLC now owns 18,591 shares of the biopharmaceutical company’s stock valued at $656,000 after purchasing an additional 281 shares during the last quarter. Augustine Asset Management Inc. grew its holdings in shares of Royalty Pharma by 4.4% during the second quarter. Augustine Asset Management Inc. now owns 6,722 shares of the biopharmaceutical company’s stock worth $242,000 after purchasing an additional 283 shares during the last quarter. GAMMA Investing LLC increased its stake in shares of Royalty Pharma by 9.6% in the third quarter. GAMMA Investing LLC now owns 3,306 shares of the biopharmaceutical company’s stock valued at $117,000 after buying an additional 289 shares during the period. Hudson Bay Capital Management LP raised its holdings in Royalty Pharma by 1.0% in the 3rd quarter. Hudson Bay Capital Management LP now owns 29,384 shares of the biopharmaceutical company’s stock valued at $1,037,000 after buying an additional 289 shares during the last quarter. Finally, Merit Financial Group LLC raised its holdings in Royalty Pharma by 3.5% in the 3rd quarter. Merit Financial Group LLC now owns 9,149 shares of the biopharmaceutical company’s stock valued at $323,000 after buying an additional 306 shares during the last quarter. 54.35% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have recently weighed in on RPRX. Morgan Stanley dropped their target price on Royalty Pharma from $55.00 to $54.00 and set an “overweight” rating for the company in a research report on Friday, October 10th. TD Cowen boosted their price objective on Royalty Pharma from $42.00 to $45.00 and gave the stock a “buy” rating in a report on Thursday, December 11th. Cowen restated a “buy” rating on shares of Royalty Pharma in a research report on Thursday, December 11th. Weiss Ratings cut shares of Royalty Pharma from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Saturday, October 25th. Finally, The Goldman Sachs Group assumed coverage on shares of Royalty Pharma in a research note on Tuesday, September 30th. They set a “buy” rating and a $42.00 price target for the company. Five analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $45.60.

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.